LON:VAL ValiRx (VAL) Share Price, News & Analysis → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free VAL Stock Alerts GBX 3.58 -0.27 (-6.88%) (As of 04:19 PM ET) Add Compare Share Share Today's Range 3.50▼ 3.8050-Day Range 3.55▼ 5.5052-Week Range 3.46▼ 15Volume888,756 shsAverage Volume730,351 shsMarket Capitalization£4.74 millionP/E RatioN/ADividend Yield0.63%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get ValiRx alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About ValiRx Stock (LON:VAL)ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.Read More VAL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAL Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comValiRx (LON:VAL) Shares Cross Below 200 Day Moving Average of $7.19February 28, 2024 | msn.comNew method discovered to halt active cancer cellsMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… February 27, 2024 | uk.news.yahoo.comScientists discover 'two-punch' method to eliminate cancer cellsFebruary 13, 2024 | lse.co.ukValiRx says requisition notice from shareholder group is invalidFebruary 9, 2024 | lse.co.ukTRADING UPDATES: ValiRx receives shareholder request for board changeDecember 5, 2023 | markets.businessinsider.comEuropean Stocks Close Mostly HigherDecember 5, 2023 | markets.businessinsider.comEuropean Markets Move Mostly HigherMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…December 5, 2023 | lse.co.ukValiRx says ValiSeek inks deal to licence VAL401 drug with AmbroseNovember 15, 2023 | morningstar.comValiRx PLC EAJFNovember 10, 2023 | lse.co.ukValiRx signs deal to evaluate StingRay Bio drug candidatesOctober 6, 2023 | lse.co.ukCORRECT (Oct 5): ICG Enterprise ups interim payout on better resultsOctober 6, 2023 | lse.co.ukValiRx sees no reason for shares jump; notes TheoremRx mulls mergerSeptember 11, 2023 | finance.yahoo.comVAL.L - ValiRx plcAugust 24, 2023 | lse.co.ukValiRx interim loss widens as costs increase; hails Inaphaea progressAugust 24, 2023 | marketwatch.comValiRx Shares Rise on Higher Income Expectations From Inaphaea BioLabsAugust 14, 2023 | lse.co.ukValiRx signs collaborative services agreement with AgilityAugust 14, 2023 | marketwatch.comValiRx Shares Rise After Collaborative Services Agreement With AgilityJuly 19, 2023 | marketwatch.comValiRx Shares Rise After Subsidiary Secures ContractJune 28, 2023 | lse.co.ukTRADING UPDATES: All Things Considered raises funds to buy SandbagJune 16, 2023 | lse.co.ukValiRx shares drop after cancer drug research droppedJune 16, 2023 | marketwatch.comValiRx Shares Fall After Cancer-Drug Development AbandonedJune 8, 2023 | marketwatch.comValiRx Changes IP Exclusivity Terms With TheoremRx to Exclude Greater ChinaJune 7, 2023 | lse.co.ukValiRx expands cancer research agreement with University of BarcelonaJune 3, 2023 | lse.co.ukSelf Storage Gr Share ChatMay 4, 2023 | msn.comMilner Therapeutics Institute welcomes Cathy Tralau-Stewart as executive directorSee More Headlines Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/07/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:VAL CUSIPN/A CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.39% Return on Assets-47.22% Debt Debt-to-Equity Ratio0.73 Current Ratio13.37 Quick Ratio1.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.06 per share Price / Cash Flow62.50 Book ValueGBX 4 per share Price / Book0.90Miscellaneous Outstanding Shares132,350,000Free FloatN/AMarket Cap£4.74 million OptionableNot Optionable Beta0.63 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Suzanne J. Dilly B.Sc. (Age 46)BSc, Ph.D., CEO & Director Comp: $160.85kMr. James Gerry Desler FCA (Age 68)CFO, Company Secretary & Executive Director Comp: $53kMr. Kumar NawaniHead of OperationsDr. Catherine Jane Tralau-Stewart Ph.D.Chief Scientific Officer & Board ObserverMr. Tarquin EdwardsHead of Investor Relations & CommunicationsMr. Mark TreharneCorporate Development ManagerMore ExecutivesKey CompetitorsOxford Cannabinoid TechnologiesLON:OCTPGenflow BiosciencesLON:GENFIXICOLON:IXIFusion AntibodiesLON:FABBSF EnterpriseLON:BSFAView All Competitors VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed in 2024? ValiRx's stock was trading at GBX 5.90 at the start of the year. Since then, VAL shares have decreased by 39.2% and is now trading at GBX 3.59. View the best growth stocks for 2024 here. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) posted its quarterly earnings results on Monday, September, 7th. The company reported ($4.43) EPS for the quarter. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR). How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:VAL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.